DANIEL ROTH: Open Payments
NPI 1699814350 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$404 in 16 payments from 8 companies in 2025. Trend: 2023 $151 · 2024 $536 · 2025 $404
Food & beverage: $404
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $105 |
| Novo Nordisk Inc | 4 | $104 |
| PFIZER INC. | 3 | $72 |
| SANOFI PASTEUR INC. | 1 | $29 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
| GlaxoSmithKline, LLC. | 1 | $26 |
| ABBVIE INC. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
Products named: MOUNJARO, ELIQUIS, JARDIANCE, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, Ozempic, AIRSUPRA, SHINGRIX, Wegovy.
Industry payments across CA — which companies pay providers there.
